Quality of Life in Immune Thrombocytopenic Purpura: China Perspectives

  • R. Yang
  • Z. Zhou
Reference work entry


Idiopathic thrombocytopenic purpura (ITP) is classified as an autoimmune bleeding disease. It is characterized by mucocutaneous bleeding due to the low platelet count. For achieving hemostatic platelet counts, main treatment measures include oral corticosteroids, intravenous immunoglobulin (IVIg), splenectomy and other immunosuppressive agents in ITP. Currently, in addition to platelet count, many other outcome measures including health-related quality of life (HRQOL) assessing were paid attention in patients with ITP. Children ITP-special instruments, such as ITP-QOL, Kids’ ITP Tools (KIT), and instrument for adults with ITP (ITP-PAQ) were developed recently. The HRQOL was assessed also in patients with ITP by a generic instrument Short-Form 36 (SF-36). The HRQOL of patients with ITP was worse than national norms. The HRQOL of patients with ITP may correlate with the duration of disease, platelet count level, and fear of bleeding, side effects of treatment, splenectomy and economic burden from this disease but not the symptom of bleeding itself. The HRQOL measurement in patients with ITP may help to stimulate the development of newer treatment measures and will allow the option of clinical treatment measures to be based more on scientific data than treatment philosophy.


Idiopathic Thrombocytopenic Purpura Idiopathic Thrombocytopenic Purpura Patient Chronic Idiopathic Thrombocytopenic Purpura Mucocutaneous Bleeding Refractory Idiopathic Thrombocytopenic Purpura 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

List of Abbreviations:



AMG 531

a thrombopoiesis stimulating fc-peptide fusion protein


intravenous anti-Rho (D)


Bother-Physical Health


bone marrow transplantation


body pain


the center for epidemiologic studies depression scale


child health questionnaire-child form




E-aminocaproic acid






general health perception


a Hemophilia-Specific Instrument For Children


health-related quality of life




idiopathic (immune) thrombocytopenic purpura


The Immune Thrombocytopenic Purpura Patient Assessment Questionnaire


a disease-specific quality of life questionnaire for children and adolescents with idiopathic thrombocytopenic purpura


intravenous immunoglobulin


a generic instrument of quality of life designed for children 8–16 years of age


kids’ ITP tools


mental health


Pediatric Quality of Life Inventory


physical functioning


psychological health


quality of life


role limitations due to emotional problems


women’s reproductive health


role limitations due to physical problems




social activity


social functioning


Short-Form 36










  1. Arnold DM, Kelton JG. (2007). Semin Hematol. 44: S12–S23.PubMedCrossRefGoogle Scholar
  2. Barnard D, Woloski M, Feeny D, McCusker P, Wu J, David M, Bussel J, Lusher J, Wakefield C, Henriques S, Blanchette V. (2003). J Pediatr Hematol Oncol. 25: 56–62.PubMedCrossRefGoogle Scholar
  3. Baronci C, Pansini V, Funaro D, Coletti V, Caruso R, Rossi GD. (2006). Pediatr Blood Cancer. 47 Suppl 5: 665–7.PubMedCrossRefGoogle Scholar
  4. Buchanan GR, Adix L. (2001). Semin Thromb Hemost. 27: 277–285.PubMedCrossRefGoogle Scholar
  5. Buchanan GR, Adix L. (2006). Pediatr Blood Cancer. 47 Suppl 5: 681–684.PubMedCrossRefGoogle Scholar
  6. Buchanan GR, Journeycake JM, Adix L. (2003). Semin Thromb Hemost. 29: 595–603.PubMedCrossRefGoogle Scholar
  7. Bussel JB. (2002). Blood Rev. 16: 31–36.PubMedCrossRefGoogle Scholar
  8. Cines DB, Blanchette VS. (2002). N Engl J Med. 346: 995–1008.PubMedCrossRefGoogle Scholar
  9. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. (2000). Arch Intern Med. 160: 1630–1638.PubMedCrossRefGoogle Scholar
  10. Cooper N, Woloski BM, Fodero EM, Novoa M, Leber M, Beer JH, Bussel JB. (2002). Blood. 99: 1922–1927.PubMedCrossRefGoogle Scholar
  11. Cortelazzo S, Finazzi G, Buelli M, Molteni A, Viero P,Barbui T. (1991). Blood. 77: 31–33.PubMedGoogle Scholar
  12. Del Vecchio GC, De Santis A, Giordano P, Amendola G, Baronci C, Del Principe D, Nobili B, Jankovic M, Ramenghi U, Russo G, Zecca M, De Mattia D. (2008). Acta Haematol. 119: 1–7.PubMedCrossRefGoogle Scholar
  13. Eiser C, Morse R. (2001). Arch Dis Child. 84: 205–211.PubMedCrossRefGoogle Scholar
  14. Fogarty PF, Segal JB. (2007). Curr Opin Hematol. 14: 515–519.PubMedCrossRefGoogle Scholar
  15. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, Blanchette VS, Bussel JB, Cines DB, Kelton JG, Lichtin AE, McMillan R, Okerbloom JA, Regan DH, Warrier I. (1996). Blood. 88: 3–40.PubMedGoogle Scholar
  16. Godeau B, Provan D, Bussel J. (2007). Curr Opin Hematol. 14: 535–556.PubMedCrossRefGoogle Scholar
  17. Klaassen RJ, Blanchette VS, Barnard D, Wakefield CD, Curtis C, Bradley CS, Neufeld EJ, Buchanan GR, Silva MP, Chan AK, Young NL. (2007). J Pediatr. 150: 510–515.PubMedCrossRefGoogle Scholar
  18. Kojouri K, Vesely SK, Terrell DR, George JN. (2004). Blood. 104: 2623–2634.PubMedCrossRefGoogle Scholar
  19. Li L, Wang HM, Shen Y. (2003). J Epidemiol Community Health. 57: 259–263.PubMedCrossRefGoogle Scholar
  20. Liu Y, Rao K. (2006). J Health Polit Policy Law. 31: 71–92.PubMedCrossRefGoogle Scholar
  21. Mathias SD, Bussel JB, George JN, McMillan R, Okano GJ, Nichol JL. (2007a). Health Qual Life Outcomes. 5: 11.PubMedCrossRefGoogle Scholar
  22. Mathias SD, Bussel JB, George JN, McMillan R, Okano GJ, Nichol JL. (2007b). Clin Ther. 29: 950–962.PubMedCrossRefGoogle Scholar
  23. Mathias SD, Gao SK, Miller KL, Cella D, Snyder C, Turner R, Wu A, Bussel JB, George JN, McMillan R, Kholos Wysocki D, Nichol JL. (2008). Health Qual Life Outcomes. 6: 13.PubMedCrossRefGoogle Scholar
  24. McMillan R. (1997). Ann Intern Med. 126: 307–314.PubMedGoogle Scholar
  25. McMillan R, Bussel JB, George JN, Lalla D, Nichol JL. (2008). Am J Hematol. 83: 150–154.PubMedCrossRefGoogle Scholar
  26. Minkov M. (2006). Pediatr Blood Cancer. 47 Suppl 5: 734–736.PubMedCrossRefGoogle Scholar
  27. Neunert CE, Buchanan GR, Blanchette VS, Barnard DR, Young NL, Curtis C, Klaassen RJ. (2006). ASH Annual Meeting Abstracts. 108: 1079.Google Scholar
  28. Nugent DJ. (2006). Hematology Am Soc Hematol Educ Program. 97–103.Google Scholar
  29. O’Brien SH, Ritchey AK, Smith KJ. (2007). Pediatr Blood Cancer. 48: 173–180.PubMedCrossRefGoogle Scholar
  30. Provan D, Newland A. (2003). J Pediatr Hematol Oncol. 25 Suppl 1: S34–S38.PubMedCrossRefGoogle Scholar
  31. Provan D, Newland AC, Norfolk D, Bolton-Maggs P, Lilleyman J, Greer I, May A, Murphy M, Ouwehand W, Watson S. (2003). Br J Haematol. 120: 574–596.CrossRefGoogle Scholar
  32. Psaila B, Bussel JB. (2007). Hematol Oncol Clin North Am. 21: 743–759, vii.PubMedCrossRefGoogle Scholar
  33. Ramenghi U, Amendola G, Farinasso L, Giordano P, Loffredo G, Nobili B, Perrotta S, Russo G, Zecca M. (2006). Pediatr Blood Cancer. 47 Suppl 5: 742–745.PubMedCrossRefGoogle Scholar
  34. Reid MM. (1995). Arch Dis Child. 72: 125–128.PubMedCrossRefGoogle Scholar
  35. Saleh MN, Grotzinger K. (2006). ASH Annual Meeting Abstracts. 108: 3291.Google Scholar
  36. Semple JW. (2002). Blood Rev. 16: 9–12.PubMedCrossRefGoogle Scholar
  37. Shad AT, Gonzalez CE, Sandler SG. (2005). Paediatr Drugs. 7: 325–336.PubMedCrossRefGoogle Scholar
  38. Simpson KN, Coughlin CM, Eron J, Bussel JB. (1998). Semin Hematol. 35: 58–64.PubMedGoogle Scholar
  39. Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. (2008). Thromb Haemost. 99: 4–13.PubMedGoogle Scholar
  40. Stasi R, Provan D. (2004). Mayo Clin Proc. 79: 504–522.PubMedCrossRefGoogle Scholar
  41. Tamminga R, Poortman G, Kamps W. (1999). Int J Pediatr Hematol Oncol. 6: 255–260.Google Scholar
  42. Tarantino MD, Bolton-Maggs PH. (2007). Curr Opin Hematol. 14: 526–534.PubMedCrossRefGoogle Scholar
  43. von Mackensen S, Nilsson C, Jankovic M, Mirra N, D’Angelo E, Borkhardt A, Ljung R. (2006). Pediatr Blood Cancer. 47: 688–691.PubMedCrossRefGoogle Scholar
  44. Wang T, Xu M, Ji L, Yang R. (2006). Acta Haematol. 115: 39–45.PubMedCrossRefGoogle Scholar
  45. Ware JE, Snow KK, Kosinski M, Gandek B. (1993). SF-36 Health Survey: Manual and Interpretation Guide. The Health Institute, New England Medical Center, Boston, MA: 465–470.Google Scholar
  46. Xu L, Wang Y, Collins CD, Tang S. (2007). BMC Health Serv Res. 7: 37.PubMedCrossRefGoogle Scholar
  47. Yang R, Han ZC. (2000). Int J Hematol. 71: 18–24.PubMedGoogle Scholar
  48. Zeller B, Rajantie J, Hedlund-Treutiger I, Tedgard U, Wesenberg F, Jonsson OG, Henter JI. (2005). Acta Paediatr. 94: 178–184.PubMedCrossRefGoogle Scholar
  49. Zhou Z, Yang L, Chen Z, Chen X, Guo Y, Wang X, Dong X, Wang T, Zhang L, Qiu Z, Yang R. (2007). Eur J Haematol. 78: 518–523.PubMedCrossRefGoogle Scholar
  50. Zhou Z, Yang R. (2008). Crit Rev Oncol Hematol. 65: 21–31.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2010

Authors and Affiliations

  • R. Yang
  • Z. Zhou

There are no affiliations available

Personalised recommendations